DOCSLIB.ORG

Maintenance Medication List Page 1 of 5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Maintenance Medication List Page 1 of 5 Maintenance Medication List Page 1 of 5 Brand Name Generic Name Brand Name Generic Name ACCOLATE zafirlukast AXID nizatidine ACCUPRIL quinapril hydrochloride AZARGA brinzolamide / timolol ACCURETIC quinapril / hydrochlorothiazide AZOPT brinzolamide ACTIVELLE estradiol / norethindrone BENURYL probenecid ACTONEL risedronate sodium BETAGAN levobunolol hydrochloride ACTOS pioglitazone hydrochloride BETOPTIC betaxolol hydrochloride ADALAT nifedipine BEVESPI formoterol / glycopyrronium ADLYXINE lixisenatide BEZALIP bezafibrate ADVAIR DISKUS fluticasone / salmeterol BONDRONAT ibandronate sodium AGGRENOX acetylsalicyclic acid / dipyridamole BREO ELLIPTA fluticasone / vilanterol AGRYLIN anagrelide hydrochloride BRILINTA ticagrelor ALDACTONE spironolactone BURINEX bumetanide ALDORIL methyldopa / hydrochlorothiazide BUSPAR buspirone hydrochloride ALLOPURINOL allopurinol BYSTOLIC nebivolol hydrochloride ALPHAGAN brimonidine tartrate CADUET amlodipine / atorvastatin ALTACE ramipril CAPOTEN captopril ALTACE HCT ramipril / hydrochlorothiazide CARDURA doxazosin mesylate ALVESCO ciclesonide CATAPRES clonidine hydrochloride AMARYL glimepiride CELEBREX celecoxib ANAFRANIL clomipramine hydrochloride CELEXA citalopram ANDROCUR cyproterone acetate CIPRALEX escitalopram oxalate ANGELIQ drospirenone / estradiol CIPRALEX MELTZ escitalopram ANORO ELLIPTA umeclidinium / vilanterol CLIMARA estradiol / levonorgestrel APRESOLINE hydralazine hydrochloride COLESTID colestipol hydrochloride ARANESP darbepoetin alfa COMBIGAN brimonidine / timolol ARAVA leflunomide COMBIVENT ipratropium / salbutamol ARICEPT donepezil hydrochloride COMTAN entacapone ARNUITY ELLIPTA fluticasone furoate CONSTELLA linaclotide ARTHROTEC diclofenac / misoprostol CONTRAVE bupropion hydrochloride / naltrexone hydrochloride ASMANEX TWISTHALER mometasone furoate CORDARONE amiodarone hydrochloride ASPIRIN acetylsalicylic acid COREG carvedilol ATACAND candesartan cilexetil COSOPT dorzolamide / timolol ATACAND PLUS candesartan / hydrochlorothiazide COVERSYL perindopril erbumine ATROVENT ipratropium bromide COVERSYL PLUS perindopril / indapamine AVALIDE irbesartan / hydrochlorothiazide COZAAR losartan potassium AVAMYS fluticasone furoate CREON pancrelipase enzyme AVANDAMET rosiglitazone / metformin CRESTOR rosuvastatin calcium AVANDARYL rosiglitazone / glimepiride CYCLEN ethinyl estradiol / norgestimate AVANDIA rosiglitazone maleate CYMBALTA duloxetine hydrochloride AVAPRO irbesartan CYTOMEL liothyronine sodium AVENTYL nortriptyline hydrochloride DAXAS roflumilast AVODART dutasteride express-scripts.ca @ExpressRxCanada Express Scripts Canada Express Scripts Canada Maintenance Medication List (continued) Page 2 of 5 Brand Name Generic Name Brand Name Generic Name DDVAP desmopressin acetate FLOMAX tamsulosin hydrochloride DEMULEN ethinyl estradiol / ethynodiol FLONASE fluticasone propionate DEPO-PROVERA medroxyprogesterone acetate FLOVENT fluticasone propionate DESYREL trazodone hydrochloride FOLVITE folic acid DETROL tolterodine tartrate FORADIL formoterol fumarate DEXILANT dexlansoprazole FORXIGA dapagliflozin DIABETA glyburide FOSAMAX alendronate sodium DIAMICRON gliclazide FOSAVANCE alendronate / vitamin d3 DIAMOX acetazolamide sodium FROBEN flurbiprofen DIANE cyproterone / ethinyl estradiol GLUCOBAY acarbose DICETEL pinaverium bromide GLUCONORM repaglinide DIDROCAL etidronate / calcium GLUCOPHAGE metformin hydrochloride DIOVAN valsartan GLYXAMBI linagliptin / empagliflozin DIOVAN-HCT valsartan / hydrochlorothiazide HYDRODIURIL hydrochlorothiazide DIPENTUM olsalazine sodium HYGROTON chlorthalidone DITROPAN oxybutynin chloride HYOSCINE hyoscine butylbromide DOPAMET methyldopa HYTRIN terazosin hydrochloride DUAKLIR GENUAIR formoterol / aclidinium bromide HYZAAR losartan / hydrochlorothiazide DUAVIVE bazedoxifene / conjugated estrogens IMDUR isosorbide mononitrate DUOTRAV travoprost / timolol INCRUSE ELLIPTA umeclidinium bromide DYAZIDE triamterene / hydrochlorothiazide INDERAL propranolol DYMISTA azelastine / fluticasone INDOCID indomethacin DYRENIUM triamterene INHIBACE cilazapril EBIXA memantine hydrochloride INHIBACE PLUS cilazapril / hydrochlorothiazide EDARBI azilsartan medoxomil INSPIOLTO RESPIMAT olodaterol / tiotropium EDARBYCLOR azilsartan / chlorthalidone INSPRA eplerenone EDECRIN ethacrynic acid INTUNIV guanfacine hydrochloride EFFEXOR venlafaxine hydrochloride INVOKAMET canagliflozin / metformin EFFIENT prasugrel hydrochloride INVOKANA canagliflozin ELAVIL amitriptyline hydrochloride IRON SUPPLEMENTS ferrous sulfate ELIQUIS apixaban ISDN isosorbide dinitrate ENABLEX darifenacin hydrobromide ISOPTIN verapamil hydrochloride ENTRESTO valsartan / sacubitril ISOPTO ATROPINE atropine sulfate ESTRACE estradiol ISOPTO CARBACHOL carbachol ESTRAGYN esterified estrogens ISOPTO CARPINE pilocarpine hydrochloride EVISTA raloxifene hydrochloride JALYN dutasteride / tamsulosin EVRA ethinyl estradiol / norelgestrom JANUMET sitagliptin / metformin EXELON rivastigmine JANUVIA sitagliptin phosphate EZETROL ezetimibe JARDIANCE empagliflozin FELDENE piroxicam JENTADUETO linagliptin / metformin FEMARA letrozole KAZANO alogliptin / metformin FEMHRT ethinyl estradiol / norethindron KOMBOGLYZE saxagliptin / metformin FETZIMA levomilnacipran hydrochloride LANOXIN digoxin express-scripts.ca @ExpressRxCanada Express Scripts Canada Express Scripts Canada Maintenance Medication List (continued) Page 3 of 5 Brand Name Generic Name Brand Name Generic Name LASIX furosemide NASONEX mometasone furoate LESCOL fluvastatin sodium NATAZIA estradiol / dienogest LIORESAL baclofen NESINA alogliptin benzoate LIPIDIL fenofibrate NEUPRO rotigotine LIPITOR atorvastatin calcium NEURONTIN gabapentin LIVOSTIN levocabastine hydrochloride NEXIUM esomeprazole LIXIANA edoxaban NIASPAN niacin LODALIS colesevelam hydrochloride NIMOTOP nimodipine LODINE etodolac NITROSTAT nitroglycerin LONITEN minoxidil NOLVADEX tamoxifen citrate LOPID gemfibrozil NORVASC amlodipine besylate LOPRESOR metoprolol tartrate NUVARING ethinyl estradiol / etonogestrel LOSEC omeprazole OLMETEC olmesartan medoxomil LOTENSIN benazepril hydrochloride OLMETEC PLUS olmesartan / hydrochlorothiazide LOZIDE indapamide OMNARIS ciclesonide LUMIGAN bimatoprost ONBREZ BREEZHALER indacaterol maleate LUVOX fluvoxamine maleate ONE-ALPHA alfacalcidol LYRICA pregabalin ONGLYZA saxagliptin hydrochloride MARVELON desogestrel / ethinyl estradiol OSENI alogliptin / pioglitazone MAVIK trandolapril OSTOFORTE ergocalciferol MEGACE megestrol acetate PANTOLOC pantoprazole sodium MEVACOR lovastatin PARIET rabeprazole sodium MEXITIL mexiletine hydrochloride PARNATE tranylcypromine sulfate MICARDIS telmisartan PAXIL paroxetine hydrochloride MICARDIS PLUS telmisartan / hydrochlorothiazide PEPCID famotidine MICRONOR norethindrone PEPTOL cimetidine MICTORYL propiverine hydrochloride PLAQUENIL hydroxychloroquine sulfate MIDAMOR amiloride hydrochloride PLAVIX clopidogrel bisulfate MIN-OVRAL ethinyl estradiol / levonorges PLENDIL felodipine MINIPRESS prazosin hydrochloride PONSTAN mefenamic acid MOBICOX meloxicam PRADAXA dabigatran MODULON trimebutine maleate PRAVACHOL pravastatin sodium MODURET amiloride / hydrochlorothiazide PREGVIT and others prenatal multivitamin MONITAN acebutolol hydrochloride PREMARIN conjugated estrogens MONOCOR bisoprolol fumarate PREMPLUS conjugated estrogens / medroxyprogesterone MONOPRIL fosinopril sodium PREVACID lansoprazole MOTRIN ibuprofen PRISTIQ desvenlafaxine succinate MULTAQ dronedarone hydrochloride PROBETA levobunolol / dipivefrin MYRBETRIQ mirabegron PROLIA denosumab NADOL nadolol PROMETRIUM progesterone NAPROSYN naproxen PROPYLTHYRACIL propylthiouracil NARDIL phenelzine sulfate PROSCAR finasteride NASACORT triamcinolone acetonide express-scripts.ca @ExpressRxCanada Express Scripts Canada Express Scripts Canada Maintenance Medication List (continued) Page 4 of 5 Brand Name Generic Name Brand Name Generic Name PROZAC fluoxetine hydrochloride TAMBOCOR flecainide acetate PULMICORT budesonide TAPAZOLE methimazole QTERN saxagliptin / dapagliflozin TECTA pantoprazole magnesium QUESTRAN cholestyramine TENORETIC atenolol / chlorthalidone QUINIDINE SULFATE quinidine sulfate TENORMIN atenolol QVAR beclomethasone dipropionate TEVETEN eprosartan mesylate RAPAFLO silodosin TEVETEN PLUS eprosartan mesylate / hydrochlorothiazide RASILEZ aliskiren fumarate TIAZAC diltiazem hydrochloride RASILEZ HCT aliskiren / hydrochlorothiazide TICLID ticlopidine hydrochloride REMERON mirtazapine TIMOPTIC timolol maleate REMINYL galantamine hydrobromide TOFRANIL imipramine hydrochloride RESOTRAN prucalopride succinate TOVIAZ fesoterodine fumarate RESTASIS cyclosporine TRAJENTA linagliptin RHINALAR flunisolide TRANDATE labetalol hydrochloride RHINOCORT budesonide TRAVATAN travoprost RIDAURA auranofin TRELEGY ELLIPTA fluticasone / umeclidinium / vilanterol ROCALTROL calcitriol TRENTAL pentoxifylline RYTHMODAN disopyramide phosphate TRINTELLIX vortioxetine hydrobromide RYTHMOL propafenone hydrochloride TROSEC trospium chloride SAFLUTAN tafluprost TRUSOPT dorzolamide hydrochloride SALAZOPYRIN sulfacetylsalicyclic acidlazine TRYPTAN l-tryptophan SALOFALK mesalazine TUDORZA GENUAIR aclidinium bromide SAXENDA liraglutide TWYNSTA telmisartan / amlodipine SEEBRI BREEZHALER glycopyrronium bromide ULORIC febuxostat SEGLUROMET ertuglifozin / metformin ULTIBRO BREEZHALER indacaterol / glycopyrronium SEREVENT salmeterol xinafoate UNIPHYL theophylline / KI SIMBRINZA brimonidine / brinzolamide VASERETIC enalapril / hydrochlorothiazide SIMVASA simvastatin / acetylsalicyclic acid VASOTEC
Load more

Recommended publications
  • Cigna Home Delivery Pharmacy Drug List
    Exclusive Cigna Home Delivery Pharmacy drug list If your prescription drug plan includes Exclusive Cigna Home Delivery Pharmacy, you are required to fill maintenance medication prescriptions (medications taken on an regular basis) through Cigna Home Delivery PharmacySM. Depending on your benefit plan, you are typically allowed three fills before you are required to use Cigna Home Delivery Pharmacy. At that time, if you choose not use Cigna Home Delivery Pharmacy, your plan will not cover the cost of your medication. To see real-time drug pricing, visit myCigna.com and use the Prescription Drug Price Quote tool to search for medications and compare pricing for your selected medications and lower-cost alternatives. The tool provides guidance on options you can discuss with your doctor and shows annual savings when you use Cigna Home Delivery Pharmacy. In addition to cost savings, Cigna Home Delivery Pharmacy offers valuable benefits, such as: • Licensed pharmacists available 24/7 • Up to a 90-day supply of medications in one fill • Standard delivery at no additional cost • Reminders if you forget to fill your prescriptions • Specialty medications, including those that require refrigeration and overnight delivery The following is a list of medications that apply to your Exclusive Cigna Home Delivery Pharmacy plan. Refer to your enrollment materials to understand the medications covered under your plan and to see if there are any requirements such as prior authorization (PA), quantity limits (QL) or Step Therapy (ST), as well as those requiring use of Cigna Home Delivery Pharmacy. If you have questions We’re here to help. Just call us at the toll-free number on your ID card and we will be happy to answer your questions.
    [Show full text]
  • WO 2010/015655 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 11 February 2010 (11.02.2010) WO 2010/015655 Al (51) International Patent Classification: sham Research Centre, Wimblehurst Road, Horsham C07C 233/79 (2006.01) C07D 277/42 (2006.01) West Sussex RH 12 5AB (GB). SVIRIDENKO, Lilya C07C 255/58 (2006.01) A61K 31/166 (2006.01) [GB/GB]; Novartis Horsham Research Centre, Wimble C07C 311/39 (2006.01) A61K 31/427 (2006.01) hurst Road, Horsham West Sussex RH 12 5AB (GB). C07D 213/74 (2006.01) A61K 31/44 (2006.01) (74) Agent: VOEGELI-LANGE, Regina; Novartis Pharma C07D 213/75 (2006.01) A61P 1/00 (2006.01) Ag, Patent Department, CH-4002 Basel (CH). C07D 213/84' (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2009/060150 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 5 August 2009 (05.08.2009) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 08162006.4 7 August 2008 (07.08.2008) EP TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME INCRUSE ELLIPTA Umeclidinium (as bromide), 62.5 micrograms, powder for inhalation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 micrograms of umeclidinium (equivalent to 74.2 micrograms umeclidinium bromide). Excipient with known effect: Each delivered dose contains approximately 12.5 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for Inhalation White powder in a grey inhaler (Ellipta) with a light green mouthpiece cover and a dose counter. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Incruse Ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 4.2 Dose and method of administration Dose Adults Incruse Ellipta (umeclidinium 62.5 micrograms) should be taken as one inhalation once daily by the orally inhaled route. Incruse Ellipta should be taken at the same time every day. Do not use Incruse Ellipta more than once every 24 hours. Special populations Elderly population No dosage adjustment is required in patients over 65 years (see 5.2 Pharmacokinetics properties– Special patient populations). 1 Renal impairment No dosage adjustment is required in patients with renal impairment (see 5.2 Pharmacokinetics properties – Special patient populations). Hepatic impairment No dosage adjustment is required in patients with mild or moderate hepatic impairment. Incruse Ellipta has not been studied in patients with severe hepatic impairment (see 5.2 Pharmacokinetics properties– Special patient populations).
    [Show full text]
  • Fasted and Fed State Human Duodenal Fluids: Characterization, Drug Solubility, and Comparison to Simulated Fluids and with Human Bioavailability
    European Journal of Pharmaceutics and Biopharmaceutics 163 (2021) 240–251 Contents lists available at ScienceDirect European Journal of Pharmaceutics and Biopharmaceutics journal homepage: www.elsevier.com/locate/ejpb Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability D. Dahlgren a, M. Venczel b,c, J.-P. Ridoux b,c, C. Skjold¨ a, A. Müllertz d, R. Holm e, P. Augustijns f, P.M. Hellstrom¨ g, H. Lennernas¨ a,* a Department of Pharmaceutical Biosciences, Biopharmaceutics, Uppsala University, Sweden b Global CMC Development Sanofi, Frankfurt, Germany c Global CMC Development Sanofi, Vitry, France d Physiological Pharmaceutics, University of Copenhagen, Copenhagen, Denmark e Drug Product Development, Janssen R&D, Johnson & Johnson, Beerse, Belgium f Drug Delivery and Disposition, KU Leuven, Leuven, Belgium g Department of Medical Sciences, Gastroenterology/Hepatology, Uppsala University, Sweden ARTICLE INFO ABSTRACT Keywords: Accurate in vivo predictions of intestinal absorption of low solubility drugs require knowing their solubility in Bioavailability physiologically relevant dissolution media. Aspirated human intestinal fluids (HIF) are the gold standard, fol­ Food effects lowed by simulated intestinal HIF in the fasted and fed state (FaSSIF/FeSSIF). However, current HIF charac­ Drug solubility terization data vary, and there is also some controversy regarding the accuracy of FaSSIF and FeSSIF for Human intestinal fluids predicting drug solubility in HIF. This study aimed at characterizing fasted and fed state duodenal HIF from 16 Drug absorption Drug dissolution human volunteers with respect to pH, buffer capacity, osmolarity, surface tension, as well as protein, phos­ Drug delivery pholipid, and bile salt content.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies
    Chinese Journal of Physiology 61(1): 1-13, 2018 1 DOI: 10.4077/CJP.2018.BAG516 Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies Tzu-Tung Chang, Chia-Jung Yang, Yu-Chi Lee, and Sheng-Nan Wu Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan, Republic of China Abstract Telmisartan (Tel) is recognized as a non-peptide blocker of AT1R. Whether this agent has any direct effects on ion currents remains unexplored. In whole-cell current recordings, addition of Tel + increased the peak amplitude of voltage-gated Na (NaV) current (INa) accompanied by the increased time constant of INa inactivation in differentiated NSC-34 motor neuron-like cells. Tel-stimulated INa in these cells is unlinked to either blockade of AT1R or activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). In order to explore how this compound affects the amplitude and kinetics of INa in neurons, a Hodgkin-Huxley-based (HH-based) model designed to mimic effect of Tel on the functional activities of neurons was computationally created in this study. In this framework, the parameter for h inactivation gating variable, which was changed in a stepwise fashion, was implemented + + to predict changes in membrane potentials (V) as a function of maximal Na (GNa), K conductance (GK), or both. As inactivation time course of INa was increased, the bifurcation point of V versus GNa became lower, and the range between subcritical and supercritical values at the bifurcation of V versus GK correspondingly became larger.
    [Show full text]
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome
    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
    [Show full text]
  • Pharmacokinetic Interactions of Pioglitazone
    Department of Clinical Pharmacology University of Helsinki Finland PHARMACOKINETIC INTERACTIONS OF PIOGLITAZONE Tiina Jaakkola ACADEMIC DISSERTATION To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in Auditorium 2 of Biomedicum, on August 24th, 2007, at 12 noon. Helsinki 2007 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 1 117.7.20077.7.2007 221:11:231:11:23 Supervisors: Professor Pertti Neuvonen, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Docent Janne Backman, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Reviewers: Docent Kimmo Malminiemi, MD, MSc Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland Professor emeritus Pertti Pentikäinen, MD Department of Medicine University of Helsinki Helsinki, Finland Opponent: Professor Kari Kivistö, MD Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland ISBN 978-952-92-2224-7 (paperback) ISBN 978-952-10-4020-7 (PDF, http://ethesis.helsinki.fi ) Helsinki 2007 Yliopistopaino JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 2 117.7.20077.7.2007 221:11:551:11:55 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 3 117.7.20077.7.2007 221:11:551:11:55 CONTENTS CONTENTS ABBREVIATIONS.......................................................................................................................................... 6 LIST OF ORIGINAL PUBLICATIONS.......................................................................................................
    [Show full text]
  • Pharmacokinetic Interactions of Drugs with St John's Wort
    http://www.paper.edu.cn Pharmacokinetic interactions of Journal of Psychopharmacology 18(2) (2004) 262–276 © 2004 British Association drugs with St John’s wort for Psychopharmacology ISSN 0269-8811 SAGE Publications Ltd, London, Thousand Oaks, CA and New Delhi 10.1177/0269881104042632 Shufeng Zhou Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Eli Chan Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Shen-Quan Pan Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore. Min Huang Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510089, PR China. Edmund Jon Deoon Lee Department of Pharmacology, Faculty of Medicine, National University of Singapore, Singapore. Abstract There is a worldwide increasing use of herbs which are often cancer patients receiving irinotecan treatment. St John’s wort did not administered in combination with therapeutic drugs, raising the alter the pharmacokinetics of tolbutamide, but increased the incidence potential for herb–drug interactions. St John’s wort (Hypericum of hypoglycaemia. Several cases have been reported that St John’s wort perforatum) is one of the most commonly used herbal antidepressants. A decreased cyclosporine blood concentration leading to organ rejection. literature search was performed using Medline (via Pubmed), Biological St John’s wort caused breakthrough bleeding and unplanned pregnancies Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their when used concomitantly with oral contraceptives. It also caused inception to September 2003) to identify known drug interaction with serotonin syndrome when coadministered with selective serotonin- St John’s wort. The available data indicate that St John’s wort is a reuptake inhibitors (e.g.
    [Show full text]
  • TAYSIDE PRESCRIBER Issue No
    TAYSIDE PRESCRIBER Issue No. 122 – May 2012 Produced by the NS Tayside Medicines Governance Unit in conjunction with Mental Health Citalopram & escitalopram:QT interval prolongation New maximum daily dose restrictions, contraindications, and warnings Information has been issued via Drug Safety Update, Volume 5, Issue 5, December 2011 and ‘Dear Healthcare Professional Letters’ for both citalopram and escitalopram regarding new restrictions on the maximum daily doses, contraindications, and warnings. This is as a result of an assessment of a QT study that revealed dose-dependent increase in the QT interval observed with ECG monitoring for both citalopram and escitalopram. Maximum licensed daily doses for citalopram and escitalopram Adults Adults > 65 years Adults with hepatic impairment Citalopram 40 mg 20 mg 20 mg Escitalopram (non-formulary) 20 mg 10 mg 10mg The guidance in NHS Tayside is: ⇒ to review all patients on high dose* citalopram or escitalopram with aim of reducing to new maximum licensed doses ( * above new maximum licensed daily doses as stated in the table above) ⇒ not to prescribe citalopram or escitalopram with other medication known to prolong the QT interval ⇒ not to prescribe citalopram and escitalopram in patients with known QT prolongation or congenital long QT syndrome ⇒ to consider alternative antidepressant in patients with cardiac disease ( e.g. patients with significant bradycardia; recent myocardial infarction or decompensated heart failure) See flow diagram on page 3 for further guidance and table below on medicines known to prolong the QT interval. Medicines known to increase plasma levels of citalopram or escitalopram, e.g. omeprazole & some antivirals may require dose reduction of citalopram or escitalopram and should be used with caution.
    [Show full text]
  • Urinary Antispasmodics TCO 02.2018
    Therapeutic Class Overview Urinary antispasmodics INTRODUCTION • Overactive bladder (OAB) is defined as urinary urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of a causative infection or pathological conditions. Urinary incontinence has been shown to greatly reduce quality of life in areas such as mental and general health in addition to physical and social functioning (American Urological Association 2019, Coyne et al 2008, Haab 2014, International Continence Society 2015). Children with OAB usually have detrusor overactivity as diagnosed through cystometric evaluation. Neurogenic detrusor overactivity is predominantly caused by a congenital neural tube defect in children (Austin et al 2016, Franco ○ et al 2020). • Behavioral therapies (eg, bladder training, bladder control strategies, pelvic floor muscle training and fluid management) are considered first-line treatment in all patients with OAB (American Urological Association 2019). • Urinary antispasmodics are used as first-line pharmacological therapy in OAB (American College of Obstetricians and Gynecologists 2015, American Urological Association 2019, Blok et al 2020, Burkhard et al 2018). Anticholinergic therapy has been frequently used in patients with neurogenic detrusor overactivity, but there are limited data in this specific population (Haab 2014). • The○ urinary antispasmodics used for the treatment of OAB belong to 2 classes of drugs, which include anticholinergic compounds known as muscarinic receptor antagonists, and the beta-3 adrenergic agonist (AR), mirabegron. The anticholinergic agents act as antagonists of acetylcholine at muscarinic cholinergic receptors, thereby relaxing smooth muscle in the bladder and decreasing bladder contractions. ○ . Oral immediate-release (IR) and extended-release (ER) formulations (LA, XL, and XR) are available for oxybutynin (Ditropan), tolterodine (Detrol), and trospium.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]